Extended in vivo activity of VRC01 HIV-1 prophylaxis entails initial protective efficacy and subsequent breakthrough infections. (science.org)

Authors: deCamp AC … Gilbert PB Journal: Science Translational Medicine Published: 2026-11-04 DOI: https://doi.org/10.1126/scitranslmed.aec3480